(Q34094632)

31 July 2017

1 reference

title

Small molecule c-Met kinase inhibitors: a review of recent patents (English)

1 reference

31 July 2017

0 references

John Porter

1

1 reference

PubMed ID

20100000

31 July 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Therapeutic Patents

31 July 2017

1 reference

31 July 2017

20

1 reference

31 July 2017

2

1 reference

31 July 2017

159-177

1 reference

Issues and progress with protein kinase inhibitors for cancer treatment

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Structural basis of hepatocyte growth factor/scatter factor and MET signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Targeting the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Chemical reactivity of methoxy 4-o-aryl quinolines: identification of glutathione displacement products in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Design, synthesis, and biological evaluation of potent c-Met inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of 4-azaindoles as novel inhibitors of c-Met kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903514137

10.1517/13543770903514137

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

20100000